KZR-616, A Selective Inhibitor of the Immunoproteasome: Preclinical and Clinical Mechanism of Action Studies in Lupus Nephritis
American Society of Nephrology (ASN Kidney Week) 2020
ASN 2020: Treatment of SLE With or Without Nephritis With the Immunoproteasome Inhibitor KZR-616: Initial Results of the MISSION Study
American Society of Nephrology (ASN Kidney Week) 2020
Preclinical evaluation of KZR-261, a novel small molecule inhibitor of Sec61
American Society of Clinical Oncology (ASCO 2020)
Blocking Protein Secretion With Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies
American Society of Hematology (ASH 2019)
Proteomic Profiling and Mechanistic Investigating of a Novel Anti-cancer Small Molecule Inhibitor of Sec61
American Society of Hematology (ASH 2019)
Treatment of Sle Patients With the Immunoproteasome Inhibitor Krz-616: Results From the First 3 Cohorts of an Open-label Phase 1b Dose Escalation Trial
American College of Rheumatology (ACR 2019)
Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of Kzr-616, a Selective Inhibitor of the Immunoproteasome
American College of Rheumatology (ACR 2019)
- « Previous
- 1
- 2
- 3
- 4
- Next »